Podcasts about Poolbeg

Poolbeg Pharma PLC (AIM:POLB) principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss the first site activation for Poolbeg's POLB 001 TOPICAL clinical trial, evaluating the drug as a preventative treatment for cytokine release syndrome (CRS), a serious side effect linked to CAR-T and bispecific antibody therapies. The UK study will enrol 30 multiple myeloma patients receiving teclistamab, with early readouts expected due to CRS typically occurring within the first two weeks of treatment. Tremble also highlighted new data presented at the EHA Congress showing POLB 001 reduced inflammatory cytokines without compromising tumour-killing activity, alongside early research suggesting potential applications in acute myeloid leukaemia (AMS). For more interviews and market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #PoolbegPharma #POLB001 #Biotech #MultipleMyeloma #AML #AcuteMyeloidLeukemia #CancerResearch #Immunotherapy #CRS #CytokineReleaseSyndrome #Teclistamab #BloodCancer #ClinicalTrials #EHA2026 #HealthcareInnovation

Poolbeg Pharma has announced the activation of the first clinical trial site for its POLB 001 TOPICAL study, marking a key operational milestone for its lead programme. The trial will evaluate POLB 001 as a potential preventative treatment for Cytokine Release Syndrome in relapsed/refractory multiple myeloma patients receiving teclistamab, an approved bispecific antibody. With recruitment now underway and interim data expected in summer 2026, the study could provide an important early readout on POLB 001's role in improving the safety and accessibility of cancer immunotherapies.

Watch on YouTubeIndependent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington joined Proactive's Stephen Gunnion to discuss the clinical-stage biopharmaceutical company's 2025 results and progress since then, highlighting a busy period for the company, with its lead POLB-001 trial now fully prepared to begin across six UK sites. The trial targets prevention of cytokine release syndrome - a serious complication of cancer immunotherapies - with patient screening imminent and interim data expected this summer. FDA orphan drug designation adds market exclusivity and financial incentives, while independent US payer research confirms multi-billion-dollar commercial potential and insurer willingness to reimburse. Partnering discussions with large and mid-sized pharma are intensifying ahead of the data readout. Skillington also flagged progress on an oral GLP-1 programme, with a proof-of-concept trial targeted for 2026. For more insights and interviews like this, visit Proactive's YouTube channel, like this video, subscribe, and turn on notifications so you never miss an update. #PoolbegPharma #JeremySkillington #Biotech #ClinicalTrials #PharmaNews #CRS #CancerImmunotherapy #DrugDevelopment #HealthcareInnovation #GLP1 #Biopharma #Investing #StockMarket #SmallCapStocks #PharmaIndustry

Watch on YouTube Poolbeg has announced some significant updates for the POLB 001 TOPICAL trial. This is a significant milestone for the company, for many reason, as chief executive Jeremy Skillington and principle scientist Liam Tremble explain

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss a pivotal moment for the company's lead asset, POLB 001. Full MHRA clearance has been secured, clearing the final regulatory hurdle before patient screening begins across six UK sites. Interim data from the trial, which targets cytokine release syndrome — a serious complication of cancer immunotherapies — is expected this summer. On the commercial side, independent US payer research confirms multi-billion-dollar peak sales potential, with insurers recognising the significant cost burden CRS places on healthcare systems. The findings are expected to strengthen Poolbeg's hand in upcoming partnership discussions. For more videos like this, visit Proactive's YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #PoolbegPharma #POLB001 #Biotech #ClinicalTrials #CRS #PharmaNews #DrugDevelopment #HealthcareInnovation #Investing #Biopharma #MHRA #CytokineReleaseSyndrome #LifeSciences

Poolbeg Pharma announces its first granted patent for POLB 001 in cancer immunotherapy-induced CRS, strengthening its global IP position. The milestone supports future partnering opportunities as the company advances toward key clinical data in 2026.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington talked with Proactive's Stephen Gunnion about the company securing its first national patent for POLB-001 targeting cancer immunotherapy-induced cytokine release syndrome (CRS). Skillington explained that the patent, granted by IP Australia, covers the use of p38 MAPK inhibitors, including POLB-001, to prevent and treat CRS. He highlighted that the protection is broad and supported by proprietary data generated by the company, following a thorough examination process. The patent marks an important milestone as Poolbeg continues expanding into oncology, building on earlier filings made in the UK and through international patent cooperation frameworks. He noted the timing aligns well with upcoming clinical developments, with interim data from its clinical trial expected in the summer. Skillington said: “The timing of this is absolutely perfect,” emphasising how the patent strengthens the company's position as it advances the programme. The discussion also outlined why intellectual property is critical for large pharmaceutical partners. Skillington explained that strong patent protection provides exclusivity and reduces uncertainty, which is essential given the significant investment required to bring drugs to market. He added that Poolbeg aims to leverage this growing IP portfolio to support future partnering opportunities. Looking ahead, the company plans to expand patent coverage into additional jurisdictions while progressing its clinical programme and delivering near-term milestones. For more videos like this, visit Proactive's YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #PoolbegPharma #POLB001 #BiotechNews #PharmaInnovation #CancerImmunotherapy #CRS #DrugDevelopment #ClinicalTrials #BiotechInvesting #IntellectualProperty #PharmaPartnerships #LifeSciences #HealthcareInnovation #OncologyResearch #BiotechStocks

Following the publication of a peer-reviewed paper in Frontiers in Immunology detailing results from the POLB 001 LPS challenge trial, we catch up with Poolbeg Pharma's CEO Jeremy Skillington and COO Liam Tremble.

Watch on YouTubeFollowing attendance at the J.P. Morgan Healthcare Conference in San Francisco, Jeremy Skillington, CEO of Poolbeg Pharma discusses the key themes shaping global healthcare in 2026 — from cancer immunotherapy and GLP-1 therapies to deal appetite and strategic partnerships — and what these insights mean for Poolbeg's strategy in the year ahead.

In this end-of-year interview, CEO Jeremy Skillington reflects on a milestone year for Poolbeg Pharma, highlighting the significant advancements made with POLB 001, including encouraging progress in the topical trial and its growing appeal to potential partners. He also discusses developments in the company's Oral GLP-1 obesity programme, one of the most pressing healthcare opportunities globally, and outlines the strengthened financial position supporting upcoming trials. Looking ahead, Jeremy explains what investors can expect in 2026, why he believes Poolbeg is strategically positioned for value-creation, and why now may be the right time for investors to pay close attention.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington and Principal Scientist Liam Tremble talked with Proactive's Stephen Gunnion about the company's involvement in the RISE research programme focused on cytokine release syndrome (CRS) in cancer immunotherapy. The University of Manchester and The Christie NHS Foundation Trust research programme titled RISE —short for Reducing Immune Stress from Excessive cytokine release from advanced therapies—is led by Dr Jonathan Lim and has received a £3.4 million grant from the UK's Medical Research Council. Skillington explained that Poolbeg Pharma will act as the lead business partner alongside Johnson & Johnson, and other partners. Poolbeg's previously announced upcoming TOPICAL trial examining its lead candidate POLB 001 will play a central role in the programme. Importantly, Johnson & Johnson will provide the approved bispecific antibody, teclistamab, for that trial. “We're very proud that POLB 001 has actually played a really key part to this,” Skillington said. Tremble noted the growing clinical challenge posed by CRS in advanced immunotherapies and how POLB 001 may offer a solution. “This really puts POLB 001 in a centrepoint position in cytokine release syndrome as a potential solution,” he said. The company confirmed the initiative will not impact its cash runway into 2027, nor will it impact delivery of the TOPICAL trial, with interim data expected in summer 2026. Visit Proactive's YouTube channel for more interviews and updates. Don't forget to like this video, subscribe, and turn on notifications to stay informed. #PoolbegPharma #POLB001 #CancerImmunotherapy #CRS #CytokineReleaseSyndrome #UKLifeSciences #BiotechNews #MedicalResearch #MRCGrant #ClinicalTrials #ImmunotherapySafety

Poolbeg Pharma (AIM: POLB) has announced that its lead asset, POLB 001, will play a central role in the new RISE research programme, a groundbreaking initiative tackling cytokine release syndrome (CRS) caused by cancer immunotherapy. In this interview, CEO Jeremy Skillington and Scientific Advisor Liam Loughrey explain what this means for the company, how the collaboration with leading academic and medical institutions came about, and what the implications are for patients and shareholders alike.

Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF) Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble talked with Share Talk's Zak Mir about the company's conference season. We recently returned from a busy conference season and wanted to share the main messages, progress and next steps for POLB001 and our oral GLP-1 programme. Between ESMO in Berlin and BioEurope in Barcelona, we gained clinical insights, interest in partnering, and clarity on trial design as we prepare for a phase 2A CRS prevention trial and a proof-of-concept study for oral GLP-1. Please see the questions for the interview: You recently attended the ESMO conference. Can you give us an overview of the conference – Liam Did you discuss POLB 001 at ESMO, and what was the general feedback? – Liam What were the key takeaways from the conference itself? – Liam Which leads me onto you, Jeremy, you just returned from BIO-Europe, how was the conference, and how do your current programmes, such as POLB 001 and your Oral GLP1 position itself, stand out at this partnering conference? - Jeremy BIO-Europe is all about connections. What types of partnerships are you seeking this year? You recently announced a collaboration with ACT to conduct your upcoming POLB 001 Phase 2a trial —so why attend the conference? Jeremy Is conference season over? Jeremy & Liam Conference calendar and next events The autumn run is not over. After BioEurope we planned continued follow ups at London Health Innovation Week and then the very significant ASH meeting in early December in Orlando. ASH is the major haemato‑oncology event where big pharma present emerging data and where clinical teams, investigators and partners congregate. We also have JP Morgan and other investor events on the horizon into the new year.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington talked with Proactive's Stephen Gunnion about the company's interim results and key clinical milestones. Skillington highlighted that Poolbeg ended June with £10 million in cash, supported by an upsized and oversubscribed £4.87 million fundraise earlier in the year. He said this extends the company's cash runway into 2027, providing a strong foundation for advancing upcoming trials. One of the company's main focuses is POLB 001, which is being developed to prevent cytokine release syndrome in patients undergoing cancer immunotherapies. “We expect to have interim data in the summer of 2026 that we can start sharing with our pharma colleagues,” Skillington noted. The trial will take place at the Christie NHS Foundation Trust under Dr Emma Searle, with support from Accelerating Clinical Trials (ACT). Skillington also discussed Poolbeg's oral GLP-1 program, developed in partnership with AnaBio Technologies. This program uses an encapsulation technology to allow oral delivery of GLP-1, currently given mostly by injection. A rapid proof-of-concept trial is planned under Prof Carel le Roux at the University of Ulster, with data expected in the first half of 2026. Looking ahead, Skillington said Poolbeg is entering a “catalyst-rich period” with multiple updates expected that could attract pharmaceutical partners. For more interviews and updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and turn on notifications to stay informed. #PoolbegPharma #POLB001 #GLP1 #CancerImmunotherapy #Biotech #ClinicalTrials #Oncology #ObesityTreatment #DrugDevelopment #PharmaInnovation

Watch on YouTube Poolbeg Pharma #POLB CEO Jerremy Skillington discusses the company's H1 2025 results, a major update on POLB 001, and progress in the high-growth GLP-1 obesity space. A strong pipeline and multiple catalysts make this a story to watch

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble talked with Proactive's Stephen Gunnion about the company's upcoming Phase 2a trial for POLB001. Tremble explained that Poolbeg has partnered with Accelerating Clinical Trials (ACT) in the UK to conduct the study, which will be led by Dr Emma Searle at the University of Manchester and the NHS Christie Foundation Trust. The Christie is one of Europe's largest cancer centres, treating more than 60,000 patients annually, and will act as the lead site. Tremble emphasised, “We've been really fortunate and feel quite blessed that we found a massive amount of interest in participating on this trial.” The trial will be a single-arm, open-label Phase 2a study involving approximately 30 patients. With sufficient supply of both POLB001 and the required bispecific antibody, Poolbeg expects to generate data throughout 2026, with a focus on safety and efficacy. Skillington noted the wider potential for POLB001 in cancer immunotherapy. He said that reducing cytokine release syndrome could allow treatments to move beyond specialist centres into community hospitals. “We feel POLB001 can do that,” he added, describing the market opportunity as greater than $10 billion. He also highlighted that the company holds FDA orphan drug designation for POLB001 and has a cash runway into 2027, positioning Poolbeg to achieve multiple milestones and advance partnering discussions. For more interviews and updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and enable notifications for future content. #PoolbegPharma #POLB001 #CancerResearch #Immunotherapy #ClinicalTrials #Biotech #Oncology #BloodCancer #PharmaNews #DrugDevelopment

Watch on YouTube Poolbeg Pharma CEO Jeremy Skillington and Liam discuss the execution plan for their upcoming Phase 2a trial of POLB 001, a promising candidate in cancer immunotherapy. They detail the trial design, the selection of clinical partners, and the potential impact of the drug. Jeremy also outlines what investors can expect in the near term as the programme advances.

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company's ambitious pipeline and strategic direction.

Poolbeg Pharma, named after the infamous Red & white towers has been working on some very exciting new ideas including a new cancer immunity drug and a potential weight loss tablet. But most early drug developments fail to make it to the final round of testing on humans because it's so risky and so expensive. And what does a pharma company like Poolbeg make of the EU-US trade deal with its 15% tariffs thus far? Jeremy Skillington, is the chief executive of Poolbeg pharma and joined Joe Lynam on the show this morning.

Nicola Kearns made it clear the anger parents are feeling about the rise in college fees. Siobhan O'Neill White is another unhappy parent when if comes to railway travel's fairer fares. Monica McGuinness has a three book deal with Poolbeg, as her first novel Crowfield House is published. David Sheehan looked ahead to the weekend's sporting action, classic comedy and a TV theme completed our line up this afternoon. Hosted on Acast. See acast.com/privacy for more information.

Watch on YouTube Following on from its £4.865 million raise last week, Poolbeg #POLB has announced that it has received FDA Orphan Drug Designation for POLB 001. Chief executive Jeremy Skillington joins us to tell us what it all means.

Poolbeg Pharma CEO Jeremy Skillington joined Steve Darling from Proactive to announce a significant milestone in the company's clinical development strategy: the U.S. Food and Drug Administration has granted Orphan Drug Designation to POLB 001, Poolbeg's innovative oral therapy aimed at preventing Cytokine Release Syndrome caused by T-cell engager bispecific antibody immunotherapies. POLB 001, an oral small molecule inhibitor of the IL-1 receptor, is designed to modulate the inflammatory response without suppressing the underlying anti-cancer immune activation. The FDA's Orphan Drug Designation recognizes the potential of POLB 001 to address a rare but serious medical condition, affecting fewer than 200,000 individuals annually in the United States. This designation confers a range of developmental and commercial incentives including seven years of U.S. market exclusivity post-approval, waiver of certain FDA fees, such as the Prescription Drug User Fee Act or PDUFA application fees and others. The company plans to initiate a Phase 2a clinical trial in the second half of 2025, marking the next step in evaluating POLB 001's efficacy and safety in a controlled setting. Poolbeg anticipates completing interim analysis in the first half of 2026, with topline data expected in the second half of 2026. With the Orphan Drug Designation in hand, Poolbeg is now well-positioned to advance discussions with potential partners and stakeholders as it progresses toward its clinical milestones. #proactiveinvestors #poolbegpharma #aim #polb #OrphanDrug #POLB001 #FDAApproval #CytokineReleaseSyndrome #CancerTherapy #BiotechNews #Immunotherapy #ClinicalTrials #PharmaInvesting

Watch on YouTube Vox Markets caught up with Poolbeg Pharma #POLB CEO Jeremy Skillington at the Master Investor Show, where he discussed the company's exciting progress in 2024. Jeremy highlighted strong investor engagement and shared updates on Poolbeg's two lead programmes.

Following their H1 interims for 2024, Vox Markets talks to their CEO Jeremy Skillington

Poolbeg Pharma CEO Jeremy Skillington joined Steve Darling from Proactive to announce the company's unaudited interim results for the first half of 2024, highlighting strong progress with its lead development candidate, POLB 001. As of 30 June 2024, the company reported a cash balance of £10.1 million, showcasing its prudent financial management and ability to support ongoing development initiatives. Skillington emphasized that POLB 001 is on track, with robust data demonstrating its efficacy in reducing cancer immunotherapy-induced cytokine release syndrome (CRS) in an in vivo animal model. This strengthens the company's patent portfolio, with the U.S. Patent Office recently granting Poolbeg a new patent for its Immunomodulator II, covering a class of drugs, including POLB 001, aimed at treating or preventing hypercytokinemia (cytokine storm) across a range of diseases. This patent approval enhances Poolbeg's ability to expand its intellectual property and attract potential partners. Poolbeg Pharma is actively engaging with multiple potential partners to further develop and commercialize POLB 001. Additionally, the company signed an exclusive 12-month option agreement for tPTX, a novel topical muco-adherent treatment for oral ulcers in patients suffering from Behçet's Disease. The treatment holds significant potential, with FDA Fast Track Designation, Orphan Drug Designation, and a possible 505(b)(2) approval pathway in the U.S., indicating its promising market prospects. Skillington emphasized Poolbeg's commitment to advancing its pipeline while maintaining strong financial discipline, positioning the company for future growth and partnerships in the biotech sector. #proactiveinvestors #poolbegpharma #aim #polb #RareDiseases #JeremySkillington #GLP1Receptor #CancerImmunotherapy #PharmaNews #ClinicalTrials #FDAApproval #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #RareDiseases #JeremySkillington #GLP1Receptor #CancerImmunotherapy #PharmaNews #ClinicalTrials #FDAApproval #ProactiveInvestors

John, sailing enthusiast and Commodore of the Irish Cruising Association told Brendan all about the annual Three Bridges Rally. It's when three of the bridges on the Liffey will open and lift - allowing a parade of some 45 boats to sail up-river from Poolbeg up to the Matt Talbot bridge. It's on at 3pm on the 7th of September.

Painting work on the Poolbeg Chimneys in Dublin begins this week. Having been immortalised in print, on t-shirts and even coffee mugs, why are the towers so iconic, and do they continue to divide opinion?Joining guest host Mairead Ronan to discuss is Emma Gileece, Architectural Historian.

Painting work on the Poolbeg Chimneys in Dublin begins this week. Having been immortalised in print, on t-shirts and even coffee mugs, why are the towers so iconic, and do they continue to divide opinion?Joining guest host Mairead Ronan to discuss is Emma Gileece, Architectural Historian.

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD present an overview of their current programmes and opportunities, focussing on POLB 001, data, exclusive option agreement and their AI-powered research using human viral challenge data Headquartered in London and publicly traded on the London Stock Exchange & the OTC Markets in the US AIM: POLB | OTCQB: POLBF Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines that address critical unmet medical needs. They are focused on strategically commercialising approved and marketed drugs to fund the development of a robust pipeline of innovative products, driving significant value creation. Jeremy Skillington began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech, he was responsible for executing over 40 licencing, investment and collaboration transactions.  Returning to Ireland in 2009, Jeremy led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd. In 2014 Jeremy joined German investment fund HS Lifesciences GmbH to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH. Jeremy joined Inflazome on its founding in 2016 and was instrumental in their acquisition by Roche in September 2020 for €380M (£325M) upfront and significant downstream milestones.  Jeremy studied Biochemistry at the National University of Ireland, Galway where he was awarded his Ph.D.  He performed his post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck. https://www.share-talk.com/poolbeg-pharma-plc-chief-executive-officer-jeremy-skillington-phd-talking-to-zak-mir/

Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD and Chief Business Officer, David Allmond present an overview of their current programmes and opportunities, focussing on POLB 001, their oral delivery platforms, exclusive option agreement and their AI-powered research using human viral challenge data, followed by a Q&A session. Jeremy Skillington PhD, Chief Executive Officer 00:16 - Introduction 03:06 - Programmes 04:08 - 2024 highlights David Allmond, Chief Business Officer 05:03 - POLB 001 & CRS 08:01 - POLB 001's efficacy 10:15 - POLB 001 Market Opportunity 14:17 - POLB 001 support 16:12 - Topical PTX & Behçet's Disease 18:36 - Topical PTX 12 month option 20:29 - Topical PTX Phase 2 trial Jeremy Skillington PhD, Chief Executive Officer 22:05 - Topical PTX outlook 22:48 - Oral delivery platform 25:02 - Artificial Intelligence programmes 28:13 - Investment case 29:30 - Q&A Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal. For more information, please go to www.poolbegpharma.com  or follow on Twitter and LinkedIn @PoolbegPharma.

WAKE gets musical! We welcome our first guest, musical genius Meg Logue, who has arranged and performed potentially the most melodious cover ever of The Ballad of Persse O'Reilly. We discuss gravelly voiced Irishmen, German opera, singing at wakes, and agree that we'd all like a sip of whatever Poolbeg's on. This week's readers: Meg Logue, Toby Malone Progress: 47 pages complete, 581 pages to go; 7.4% read. For early drops, community and show notes, join us at our free Patreon, at ⁠⁠⁠⁠⁠patreon.com/wakepod⁠⁠⁠⁠⁠. We welcome comments from everyone: even, nay, especially, the dreaded purists. Come and "um actually" us!

We spoke to travel editor Eoghan Corry about the implications for Red Bull after they sent three skydivers in between the Poolbeg Towers at wind speeds of 253 km/h.

Emma Gilleece, Architectural Historian.

The ESB has opened a major battery plant at its Poolbeg site in Dublin which will add 75MW (150MWh) of fast-acting energy storage to help provide grid stability and deliver more renewables on Ireland's electricity system. This latest battery energy storage system (BESS), currently the largest site of its kind in commercial operation in Ireland, is part of ESB's pipeline of projects which are being delivered at sites in Dublin and Cork - representing an investment of up to €300m. These high-capacity batteries can store excess renewable energy for discharge when required, and in doing so, help to support Ireland in reaching its ambitious climate targets by 2030 and ESB in achieving its Net Zero by 2040 strategy. This project, operational since late November 2023, has a capability of providing 75MW of energy for two hours to Ireland's electricity system. This plant is located at ESB's Poolbeg Energy Hub in Dublin where some of the latest technologies that will support the future delivery of renewable energy including batteries, hydrogen and offshore wind will be deployed over the next decade. ESB is working with partners Fluence, as well as Irish companies, Kirby Group and Powercomm Group, in the delivery of these projects at Poolbeg, Aghada, Inchicore, and South Wall - the remainder of these projects are due to be completed this year. Eamon Ryan TD, Minister for the Environment, Climate and Communications, said: "Energy storage like this major battery plant at the ESB's flagship site in Poolbeg will be a core part of Ireland's new renewable energy transition and will play a key role in balancing our new, homegrown power supply. No electricity system can operate without a backup. In Ireland this has traditionally been provided by fossil fuel generation. Jim Dollard, ESB Executive Director, Generation and Trading, outlined how the plant will support ESB's Net Zero by 2040 target: "Today marks another important milestone for ESB as we launch our latest fast-acting grid-scale battery unit that will support grid stability and help to deliver more renewables on Ireland's electricity system. The location of this project, at our Poolbeg Energy Hub, will build on our longstanding history of innovation at the site. See more stories here.

For many private European biotechs, flat or down valuations have become the new normal as they struggle to raise money despite having quality science, +ND Capital's Dani Bach said on a special edition of the BioCentury This Week podcast featuring takeaways from the 2023 Bio€quity Europe conference in Dublin. Investors, he said, are flocking to a handful of outsize fundraising rounds out of fear. In conversation Monday with Jeff Cranmer and Stephen Hansen of BioCentury and Poolbeg's Jeremy Skillington, Bach described a bipolar fundraising environment in which the “bulk of companies are struggling for money and a few are getting massive amounts of money even beyond their wild expectations.” Bach, Skillington and BioCentury's editors also discuss Ireland's burgeoning biotech ecosystem, Europe's biopharma hubs and the performance of U.K.'s biotechs listed on the London Stock Exchange. This episode is sponsored by Jeito Capital.

Poolbeg Pharma (OTCQB: POLBF) is a clinical stage infectious disease pharmaceutical company with a capital light clinical model which is looking to develop multiple products faster and more cost effectively than the conventional biotech model. CEO Jeremy Skillington joins us to discuss how the Covid-19 pandemic has impacted the company's research on infectious diseases. View Podcast Transcript for Poolbeg Pharma